China Pharma Holdings Total Revenue

The latest total revenue for CPHI is $5.9T as of March 2026. That compares with $3.2T in the prior-year period — up 86.1% year over year. That is above the Healthcare sector average of $110B. Investors often review this figure alongside China Pharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CPHI's total revenue moved from $3.2T to $5.9T — a 86.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in China Pharma Holdings's operating scale or balance-sheet position.

Against Healthcare companies, CPHI currently prints $5.9T for total revenue, while the sector average sits near $110B. That is roughly 5441.9% above the sector mean. Large gaps often invite a closer look at China Pharma Holdings's growth, margins, and balance sheet.

A total revenue figure of $5.9T for CPHI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting CPHI's total revenue ($5.9T), review year-over-year change from $3.2T, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.